From Glioblastoma Treatments
Jump to navigationJump to search
Property Information
Drug Name MDNA55
FDA Approval No
Used for Recurrent malignant gliomas
Clinical Trial Phase Early phase trials
Clinical Trial Explanation Not specified
Common Side Effects Not specified in the provided text
OS without Not specified
OS with Not specified in the provided text
PFS without Not specified
PFS with Not specified in the provided text
Usefulness Rating 3
Usefulness Explanation Not specified
Toxicity Level 2.5
Toxicity Explanation The treatment, MDNA55, is in its early phase of trials, meaning that its potential side effects are still being evaluated. Currently, it's not fully approved by the FDA and exact toxicity is not specified. However, MDNA55 is designed to target cells common in tumor tissue, creating a high potential for effectiveness with fewer harmful effects on healthy tissue. It has shown significant positive response rates, suggesting a manageable toxicity profile. Nevertheless, every treatment carries some risk, and potential side effects might still be discovered. The toxicity rating of 2.5 out of 5 indicates a moderate risk of toxic side effects at this point in time.

Notes: MDNA55, a fusion of IL-4 and Pseudomonas exotoxin A, targets cells with high IL-4R expression, common in tumor tissue. Preliminary data shows significant efficacy with a 56% response rate and a 20% complete response rate in recurrent glioblastoma patients treated with a single infusion, highlighting potential as a highly effective treatment.

From Ben Williams Book: Not specified

Loading comments...